Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
Go to Source
Author: Christina Jewett
https://rss.nytimes.com/services/xml/rss/nyt/HomePage.xml

